Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen

MeSH terms

• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• B7-H1 Antigen / antagonists & inhibitors*
• Carboplatin / administration & dosage
• Carcinoma, Transitional Cell / drug therapy
• Carcinoma, Transitional Cell / secondary*
• Carcinoma, Transitional Cell / surgery
• Chemotherapy, Adjuvant
• Cisplatin / administration & dosage
• Cisplatin / therapeutic use*
• Combined Modality Therapy
• Drug Resistance, Neoplasm
• Drug Substitution
• Female
• Humans
• Immunotherapy*
• Male
• Middle Aged
• Neoadjuvant Therapy
• Neoplasm Proteins / antagonists & inhibitors*
• Programmed Cell Death 1 Receptor / antagonists & inhibitors*
• Progression-Free Survival
• Retrospective Studies
• Salvage Therapy*
• Urologic Neoplasms / drug therapy*
• Urologic Neoplasms / surgery